300676 华大基因
已收盘 04-23 15:00:00
资讯
新帖
简况
【量价齐跌榜前十：泰鸿万立连续7天缩量下跌，累计跌幅30.68%】截至4月18日收盘，泰鸿万立量价齐跌，连续7天缩量下跌，累计跌幅30.68%。其余量价齐升的上涨个股还包括：新希望（缩量下跌6天）、ST天山（缩量下跌6天）、锦浪科技（缩量下跌6天）、北京文化（缩量下跌5天）、海鸥住工（缩量下跌5天）、纳思达（缩量下跌5天）、科伦药业（缩量下跌5天）、新雷能（缩量下跌5天）、华大基因（缩量下跌5天）。
金融界 · 04-18
【量价齐跌榜前十：泰鸿万立连续7天缩量下跌，累计跌幅30.68%】截至4月18日收盘，泰鸿万立量价齐跌，连续7天缩量下跌，累计跌幅30.68%。其余量价齐升的上涨个股还包括：新希望（缩量下跌6天）、ST天山（缩量下跌6天）、锦浪科技（缩量下跌6天）、北京文化（缩量下跌5天）、海鸥住工（缩量下跌5天）、纳思达（缩量下跌5天）、科伦药业（缩量下跌5天）、新雷能（缩量下跌5天）、华大基因（缩量下跌5天）。
华大基因：目前公司业务暂未涉及DNA存储及DNA计算机方面的研究
证券之星 · 03-11
华大基因：目前公司业务暂未涉及DNA存储及DNA计算机方面的研究
华大基因：截至2024年10月31日公司的普通股股东总数为65696人
证券之星 · 03-11
华大基因：截至2024年10月31日公司的普通股股东总数为65696人
华大基因：公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案
证券之星 · 03-11
华大基因：公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案
华大基因：如公司有相关资本规划，将在巨潮资讯网发布公告，及时履行信息披露义务
证券之星 · 03-11
华大基因：如公司有相关资本规划，将在巨潮资讯网发布公告，及时履行信息披露义务
诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议
智通财经 · 03-07
诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议
华大基因与诺唯赞签署合作协议
美港电讯 · 03-07
华大基因与诺唯赞签署合作协议
【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股（附名单）
证券之星 · 03-06
【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股（附名单）
【机构调研记录】光大保德信基金调研华大基因
证券之星 · 03-06
【机构调研记录】光大保德信基金调研华大基因
【机构调研记录】万家基金调研华大基因
证券之星 · 03-06
【机构调研记录】万家基金调研华大基因
华大基因：财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司
证券之星 · 03-05
华大基因：财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司
3月4日华大基因涨8.39%，万家经济新动能混合A基金重仓该股
证券之星 · 03-04
3月4日华大基因涨8.39%，万家经济新动能混合A基金重仓该股
A股基因测序概念股局部活跃，华大智造涨超14%，贝瑞基因此前涨停，华大基因、达安基因、迪安诊断等跟涨。
美港电讯 · 03-04
A股基因测序概念股局部活跃，华大智造涨超14%，贝瑞基因此前涨停，华大基因、达安基因、迪安诊断等跟涨。
华大基因入选高盛“中国AI医疗保健指数”： 基因科技正迎来变革的突破性时刻
每日经济新闻 · 03-03
华大基因入选高盛“中国AI医疗保健指数”： 基因科技正迎来变革的突破性时刻
华大基因（300676）股东深圳华大基因科技有限公司质押450万股，占总股本1.08%
证券之星 · 03-03
华大基因（300676）股东深圳华大基因科技有限公司质押450万股，占总股本1.08%
华大基因：Goldman Sachs - GIR US、Greenwoods Asset Mgmt HK Ltd等多家机构于2月28日调研我司
证券之星 · 03-03
华大基因：Goldman Sachs - GIR US、Greenwoods Asset Mgmt HK Ltd等多家机构于2月28日调研我司
中国生物科技服务与深圳华大基因科技订立战略合作框架协议
新浪港股 · 02-26
中国生物科技服务与深圳华大基因科技订立战略合作框架协议
【中国生物科技服务(08037.HK)与深圳华大基因科技订立战略合作框架协议】中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。
金融界 · 02-25
【中国生物科技服务(08037.HK)与深圳华大基因科技订立战略合作框架协议】中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。
中国生物科技服务(08037)与深圳华大基因科技订立战略合作框架协议
智通财经 · 02-25
中国生物科技服务(08037)与深圳华大基因科技订立战略合作框架协议
AMAC科研技术指数下跌1.15%，前十大权重包含华大基因等
金融界 · 02-25
AMAC科研技术指数下跌1.15%，前十大权重包含华大基因等
加载失败，点击重试
公司概况
公司名称：
深圳华大基因股份有限公司
所属行业：
专业技术服务业
上市日期：
2017-07-14
主营业务：
深圳华大基因股份有限公司的主营业务为通过基因检测,质谱检测,生物信息分析等多组学大数据技术手段，为科研机构,企事业单位,医疗机构,社会卫生组织等提供研究服务和精准医学检测综合解决方案。公司主要产品包括孕期营养检测、人体氨基酸检测、人体维生素检测等。公司荣获“2022年度ESG最佳社会责任企业”、“2023医疗器械出海最佳战略布局企业”、“2022年度投资者关系金奖杰出IR公司”，“2023环境、社会及治理（ESG）年度案例”等多项社会荣誉或奖项，有效提升了公司的品牌知名度和影响力。
发行价格：
13.64
{"stockData":{"symbol":"300676","market":"SZ","secType":"STK","nameCN":"华大基因","latestPrice":48.53,"timestamp":1745391807000,"preClose":48.2,"halted":0,"volume":3651599,"delay":0,"changeRate":0.0068,"floatShares":413000000,"shares":416000000,"eps":-0.2444,"marketStatus":"已收盘","change":0.33,"latestTime":"04-23 15:00:00","open":48.62,"high":49.28,"low":48.26,"amount":178000000,"amplitude":0.0212,"askPrice":48.54,"askSize":34,"bidPrice":48.53,"bidSize":74,"shortable":0,"etf":0,"ttmEps":-0.2444,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745458200000},"marketStatusCode":5,"adr":0,"adjPreClose":48.2,"symbolType":"stock","openAndCloseTimeList":[[1745371800000,1745379000000],[1745384400000,1745391600000]],"highLimit":53.02,"lowLimit":43.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":415821575,"isCdr":false,"pbRate":2.04,"roa":"--","roe":"--","epsLYR":0.2266,"committee":0.374046,"marketValue":20180000000,"turnoverRate":0.0089,"status":0,"floatMarketCap":20020000000},"requestUrl":"/m/hq/s/300676/tweets","defaultTab":"tweets","newsList":[{"id":"2528304940","title":"【量价齐跌榜前十：泰鸿万立连续7天缩量下跌，累计跌幅30.68%】截至4月18日收盘，泰鸿万立量价齐跌，连续7天缩量下跌，累计跌幅30.68%。其余量价齐升的上涨个股还包括：新希望（缩量下跌6天）、ST天山（缩量下跌6天）、锦浪科技（缩量下跌6天）、北京文化（缩量下跌5天）、海鸥住工（缩量下跌5天）、纳思达（缩量下跌5天）、科伦药业（缩量下跌5天）、新雷能（缩量下跌5天）、华大基因（缩量下跌5天）。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528304940","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528304940?lang=zh_cn&edition=full","pubTime":"2025-04-18 16:42","pubTimestamp":1744965775,"startTime":"0","endTime":"0","summary":"截至4月18日收盘，泰鸿万立量价齐跌，连续7天缩量下跌，累计跌幅30.68%。其余量价齐升的上涨个股还包括：新希望（缩量下跌6天）、ST天山（缩量下跌6天）、锦浪科技（缩量下跌6天）、北京文化（缩量下跌5天）、海鸥住工（缩量下跌5天）、纳思达（缩量下跌5天）、科伦药业（缩量下跌5天）、新雷能（缩量下跌5天）、华大基因（缩量下跌5天）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18164249658223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002084","002422","BK0196","BK0093","LU1064130708.USD","603210","BK0046","300676","BK0137","BK0125","BK0186","BK0092","BK0038","BK0177","BK0077","BK0117","BK0060","LU1064131003.USD","BK0087","BK0042","300313","000876","000802","BK0214","002180","300763","BK0240","BK0238","BK0188","300593","BK0183","BK0098","BK0012","BK0197","BK0221","BK0256","BK0264","LU2148510915.USD","BK0028","BK0139","BK0267","BK0224","BK0239","BK0187"],"gpt_icon":0},{"id":"2518760634","title":"华大基因：目前公司业务暂未涉及DNA存储及DNA计算机方面的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2518760634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518760634?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:39","pubTimestamp":1741678764,"startTime":"0","endTime":"0","summary":"证券之星消息，华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，我了解到我们公司有有关DNA存储技术对吧？我还想了解一下有没有生物计算机或DNA计算机方面的研究呢？多谢华大基因回复：您好，感谢您对华大基因的关注。目前公司业务暂未涉及DNA存储及DNA计算机方面的研究。谢谢。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100022667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","300676","BK0221","BK0197","159998","BK0046","BK0042"],"gpt_icon":0},{"id":"2518750762","title":"华大基因：截至2024年10月31日公司的普通股股东总数为65696人","url":"https://stock-news.laohu8.com/highlight/detail?id=2518750762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518750762?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678284,"startTime":"0","endTime":"0","summary":"证券之星消息，华大基因03月11日在投资者关系平台上答复投资者关心的问题。顺祝你们，身体健康，万事如意, 【比如截至到2025年2月20日贵公司的股东人数是多少？】.华大基因回复：您好，感谢您对华大基因的关注。根据公司发布的《2024年三季度报告》，截至2024年10月31日，公司的普通股股东总数为65696人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","300676","BK0197","BK0042","BK0221"],"gpt_icon":0},{"id":"2518762723","title":"华大基因：公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518762723?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678270,"startTime":"0","endTime":"0","summary":"证券之星消息，华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司，有无涉及机器人业务。华大基因回复：您好，感谢您对华大基因的关注。公司主营业务为通过基因检测、质谱检测、生物信息分析等多组学大数据技术手段，为科研机构、企事业单位、医疗机构、社会卫生组织等提供研究服务和精准医学检测综合解决方案。谢谢。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0197","BK0196","BK0221","159739","300676"],"gpt_icon":0},{"id":"2518762291","title":"华大基因：如公司有相关资本规划，将在巨潮资讯网发布公告，及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518762291?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678270,"startTime":"0","endTime":"0","summary":"证券之星消息，华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：当前鼓励上市公司对有协同性业务的公司进行并购重组，公司是否有这方面的考虑。华大基因回复：您好，感谢您对华大基因的关注。如公司有相关资本规划，将在巨潮资讯网发布公告，及时履行信息披露义务。谢谢。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0221","300676","BK0042","BK0197","BK0196","BK0046"],"gpt_icon":0},{"id":"2517310414","title":"诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2517310414","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517310414?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:52","pubTimestamp":1741341147,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺唯赞(688105.SH)发布公告，公司与华大基因(300676.SZ)近日于深圳市签署了《战略合作协议》，拟依托各自的专业技术、行业地位和资源优势，在生殖遗传、肿瘤防控、慢性疾病管理以及感染防控等业务方向进行战略合作。本次协议签订，双方将聚焦生命科学、体外诊断领域，旨在通过优势互补，共同推动技术创新与产品应用落地，在主动健康管理、以心脑血管疾病为代表的慢性病防控等领域加深合作，共同促进我国生物科技协同发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","300676","BK0197","BK0042","688105","BK0196","BK0221","BK0046"],"gpt_icon":0},{"id":"2517124464","title":"华大基因与诺唯赞签署合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2517124464","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517124464?lang=zh_cn&edition=full","pubTime":"2025-03-07 13:46","pubTimestamp":1741326395,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159837","BK0135","BK0216","BK0160","BK0101","BK0147","BK0197","BK0221","BK0042","BK0046","300676","BK0218","BK0196","300152","688105"],"gpt_icon":0},{"id":"2517976631","title":"【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976631?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:08","pubTimestamp":1741219729,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月5日披露的机构调研信息，华安基金近期对3家上市公司进行了调研，相关名单如下：1）华大基因 调研纪要：华大基因已将AI技术应用于遗传病辅助诊断，显著提升了通量和效率，降低了生产成本。华安基金成立于1998年，截至目前，资产管理规模6543.08亿元，排名16/209；资产管理规模4237.56亿元，排名12/209；管理公募基金数508只，排名11/209；旗下公募基金经理73人，排名12/209。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0221","BK0196","300676","BK0042","BK0046","688179","BK0197"],"gpt_icon":0},{"id":"2517976571","title":"【机构调研记录】光大保德信基金调研华大基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976571?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:07","pubTimestamp":1741219626,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月5日披露的机构调研信息，光大保德信基金近期对1家上市公司进行了调研，相关名单如下：1）华大基因 调研纪要：华大基因已将AI技术应用于遗传病辅助诊断，显著提升了通量和效率，降低了生产成本。光大保德信基金成立于2004年，截至目前，资产管理规模757.36亿元，排名72/209；资产管理规模569.61亿元，排名67/209；管理公募基金数135只，排名53/209；旗下公募基金经理21人，排名66/209。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676","BK0221","BK0197","BK0046","BK0042","BK0196"],"gpt_icon":0},{"id":"2517976620","title":"【机构调研记录】万家基金调研华大基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976620?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:01","pubTimestamp":1741219295,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月5日披露的机构调研信息，万家基金近期对1家上市公司进行了调研，相关名单如下：1）华大基因 调研纪要：华大基因已将AI技术应用于遗传病辅助诊断，显著提升了通量和效率，降低了生产成本。万家基金成立于2002年，截至目前，资产管理规模4951.74亿元，排名25/209；资产管理规模1705.08亿元，排名31/209；管理公募基金数322只，排名20/209；旗下公募基金经理42人，排名26/209。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0197","300676","BK0046","BK0221","BK0196"],"gpt_icon":0},{"id":"2517955731","title":"华大基因：财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2517955731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517955731?lang=zh_cn&edition=full","pubTime":"2025-03-05 11:30","pubTimestamp":1741145456,"startTime":"0","endTime":"0","summary":"华大基因在算力部署上有长期积累和合作伙伴关系，包括与超算中心和GPU卡供应商的合作，可以满足临时大规模训练和日常研发需求。华大基因主营业务：通过基因检测、质谱检测、生物信息分析等多组学大数据技术手段,为科研机构、企事业单位、医疗机构、社会卫生组织等提供研究服务和精准医学检测综合解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500016054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK1583","BK1258","09983","BK0201","BK0012","BK0276","BK0197","BK1229","BK0042","BK1542","BK0196","300676","BK0188","BK0028","601099","BK0077","BK0221","BK0046"],"gpt_icon":0},{"id":"2516964248","title":"3月4日华大基因涨8.39%，万家经济新动能混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516964248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516964248?lang=zh_cn&edition=full","pubTime":"2025-03-04 16:26","pubTimestamp":1741076793,"startTime":"0","endTime":"0","summary":"证券之星消息，3月4日华大基因涨8.39%，收盘报65.91元，换手率5.64%，成交量23.25万手，成交额14.8亿元。3月4日的资金流向数据方面，主力资金净流入1.89亿元，占总成交额12.79%，游资资金净流入1171.42万元，占总成交额0.79%，散户资金净流出2.01亿元，占总成交额13.58%。重仓华大基因的公募基金请见下表：根据2024基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为万家经济新动能混合A。该公募基金现任基金经理为黄兴亮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400027453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0197","BK0221","300676","BK0042"],"gpt_icon":0},{"id":"2516361100","title":"A股基因测序概念股局部活跃，华大智造涨超14%，贝瑞基因此前涨停，华大基因、达安基因、迪安诊断等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516361100","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516361100?lang=zh_cn&edition=full","pubTime":"2025-03-04 13:27","pubTimestamp":1741066061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0197","688114","BK0188","000710","BK0042","BK0070","BK0046","BK0102","BK0168","BK0221","BK0139","BK0114","BK0236","002030","BK0251","BK0122","399300","300244","BK0159","300676","BK0186","BK0081","BK0146","BK0086","BK0028","159982","BK0239","BK0196"],"gpt_icon":0},{"id":"2516314662","title":"华大基因入选高盛“中国AI医疗保健指数”： 基因科技正迎来变革的突破性时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2516314662","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516314662?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:10","pubTimestamp":1741021800,"startTime":"0","endTime":"0","summary":" 今年2月以来，以DeepSeek为代表的人工智能大模型，在各个领域取得的进展引起全球关注，医疗保健行业作为大模型落地应用的重要领域尤为突出。2月19日，高盛FICC与股票部门发布《中国AI医疗指数》报告，推出高盛中国AI医疗保健指数，成分股包括华大基因等15家上市公司。2月28日，高盛等外资投资机构又马不停蹄地前往华大基因调研。华大基因作为全球基因测序领域的领跑者，正通过AI技术加速向“生命数智化平台”蜕变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-04/doc-inenmtfx5723800.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-04/doc-inenmtfx5723800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443549.SGD","LU2237443465.HKD","BK0197","LU1868837300.USD","IE00BFXG1179.USD","LU2750360641.GBP","BK4552","BK4127","LU2750360997.AUD","BK0042","BK0046","LU0096364046.USD","LU2471134796.USD","IE0034235188.USD","IE0004086264.USD","IE00B19Z3581.USD","BK0221","IE0002270589.USD","BK4588","LU1668664300.SGD","LU2237443622.USD","LU2471134952.CNY","LU0106831901.USD","LU2237438978.USD","LU1868836591.USD","BK4533","LU1791807156.HKD","LU2237443382.USD","BK4516","LU0061475181.USD","IE00B19Z3B42.SGD","LU2471134879.HKD","LU1868836757.USD","300676","LU1868836914.USD","LU2237443978.SGD","BK4504","BK4550","LU2471134523.USD","LU1868837136.USD","LU2237443895.HKD","IE0004091025.USD","IE00BSNM7G36.USD","BK4585","BK0196"],"gpt_icon":0},{"id":"2516639096","title":"华大基因（300676）股东深圳华大基因科技有限公司质押450万股，占总股本1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639096","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639096?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:08","pubTimestamp":1741010901,"startTime":"0","endTime":"0","summary":"证券之星消息，华大基因3月3日公开信息显示，股东深圳华大基因科技有限公司向中国银行股份有限公司深圳东部支行合计质押450.0万股，占总股本1.08%。质押详情见下表：截止本公告日，股东深圳华大基因科技有限公司已累计质押股份1.05亿股，占其持股总数的70.47%，股东深圳生华投资企业已累计质押股份2480.0万股，占其持股总数的71.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300033607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","300676","BK0221","BK0197","BK0046","BK0042"],"gpt_icon":0},{"id":"2516520921","title":"华大基因：Goldman Sachs - GIR US、Greenwoods Asset Mgmt HK Ltd等多家机构于2月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2516520921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516520921?lang=zh_cn&edition=full","pubTime":"2025-03-03 10:30","pubTimestamp":1740969046,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年3月1日华大基因发布公告称Goldman Sachs - GIR USMatthew Carlisle Sykes David Harrison Roman、Greenwoods Asset Mgmt HK LtdWei LI、Millennium Partners LPVincent CHANG、Polar Asset Mgmt PartnersWinston Chang、RTW InvsStefan Prendergast、Springhill Fund Asset Mgmt Co LtdJane Wu、T Rowe Price Associates Sarin Murlidar、Tiger Pacific Capital LPShu ZHU、Goldman Sachs - GIR UKRichard Felton、Goldman Sachs - GIR HKChris Pan、Goldman Sachs - GIR ChinaTianyi Yan、Goldman Sachs - Corporate AccessSherry Shi、Apex View Asset MgmtBiming Wu、Balyasny Asset MgmtOmar Zamir Will Fafinski、Citadel Global EquitiesBrendan Peters、Dymon Asia Capital HK LtdLin TANG于2025年2月28日调研我司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300006611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","300676","BK0221","BK0197","BK0042"],"gpt_icon":0},{"id":"2514902999","title":"中国生物科技服务与深圳华大基因科技订立战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514902999","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514902999?lang=zh_cn&edition=full","pubTime":"2025-02-26 08:16","pubTimestamp":1740528960,"startTime":"0","endTime":"0","summary":" 中国生物科技服务发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司订立战略合作框架协议：双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。 华大与公司在肿瘤精准诊断、治疗及技术研发领域具有互补性，并愿意基于平等互利，合作共赢，共同发展的原则开展长期战略合作。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-26/doc-inemuerp0636657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0042","BK1511","300676","BK0046","BK0197","BK1219","BK0196","BK0221","08037"],"gpt_icon":0},{"id":"2514097965","title":"【中国生物科技服务(08037.HK)与深圳华大基因科技订立战略合作框架协议】中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097965","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514097965?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:22","pubTimestamp":1740493354,"startTime":"0","endTime":"0","summary":"中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25222248383570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["08037","CAR","BK1219","BK4022","BK0197","BK0196","BK0221","BK4230","BK0042","BK0046","300676","BK1511"],"gpt_icon":0},{"id":"2514097882","title":"中国生物科技服务(08037)与深圳华大基因科技订立战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097882","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514097882?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:17","pubTimestamp":1740493070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司订立战略合作框架协议：双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。深圳华大科技作为优先合作伙伴，为公司提供肿瘤治疗后检测产品和解决方案，用于患者治疗后的效果监测评估及长期随访。海南博鳌BNCT硼中子治疗中心计划于2025年第四季度开业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK1219","BK0196","08037","BK0197","BK0042","BK0221","300676","BK1511"],"gpt_icon":0},{"id":"2514094915","title":"AMAC科研技术指数下跌1.15%，前十大权重包含华大基因等","url":"https://stock-news.laohu8.com/highlight/detail?id=2514094915","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514094915?lang=zh_cn&edition=full","pubTime":"2025-02-25 21:46","pubTimestamp":1740491175,"startTime":"0","endTime":"0","summary":"金融界2月25日消息，上证指数低开震荡，AMAC科研技术指数 下跌1.15%，报5505.8点，成交额217.35亿元。数据统计显示，AMAC科研技术指数近一个月上涨14.87%，近三个月上涨12.74%，年至今上涨13.19%。从AMAC科研技术指数持仓样本的行业来看，医药卫生占比61.91%、工业占比34.97%、信息技术占比1.40%、原材料占比1.10%、可选消费占比0.62%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25214648383365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0196","BK0197","300676","BK0042","BK0221","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745437783986,"stockEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.1133},{"period":"3month","weight":0.2664},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.2406},{"period":"ytd","weight":0.1563}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":-0.0219},{"period":"3month","weight":0.0205},{"period":"6month","weight":-0.001},{"period":"1year","weight":0.0908},{"period":"ytd","weight":-0.0165}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳华大基因股份有限公司","boardCode":"AI0074","boardName":"专业技术服务业","stockholders":"65696人(较上一季度增加0.00%)","perCapita":"6279股","listingDate":"2017-07-14","address":"广东省深圳市盐田区洪安三街21号华大综合园7栋7层-14层","registeredCapital":"41582万元","survey":" 深圳华大基因股份有限公司的主营业务为通过基因检测,质谱检测,生物信息分析等多组学大数据技术手段，为科研机构,企事业单位,医疗机构,社会卫生组织等提供研究服务和精准医学检测综合解决方案。公司主要产品包括孕期营养检测、人体氨基酸检测、人体维生素检测等。公司荣获“2022年度ESG最佳社会责任企业”、“2023医疗器械出海最佳战略布局企业”、“2022年度投资者关系金奖杰出IR公司”，“2023环境、社会及治理（ESG）年度案例”等多项社会荣誉或奖项，有效提升了公司的品牌知名度和影响力。","listedPrice":13.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华大基因(300676)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华大基因(300676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华大基因,300676,华大基因股票,华大基因股票老虎,华大基因股票老虎国际,华大基因行情,华大基因股票行情,华大基因股价,华大基因股市,华大基因股票价格,华大基因股票交易,华大基因股票购买,华大基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华大基因(300676)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华大基因(300676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}